N/A
Completed N=2,089
Vytorin Reexamination Study (0653A-174)
Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH)
Source: ClinicalTrials.gov NCT01070966 ↗
Enrolled (actual)
2,089
Serious AEs
0.8%
Results posted
May 2011
Primary outcomePrimary: Percentage of Participants With Any Clinical and/or Laboratory Adverse Experiences While Taking VYTORIN® Within 14 Days After Treatment Discontinuation — 5.72 Percentage of Participants
Summary
This survey is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of VYTORIN through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Any Clinical and/or Laboratory Adverse Experiences While Taking VYTORIN® Within 14 Days After Treatment Discontinuation |
5.72 | — |
| PRIMARY Mean Percent Change From Baseline to Treatment in Lipid Parameters |
231.31; 173.00; -23.90; 49.64; 49.85; 2.06 | — |
Eligibility Criteria
Inclusion Criteria
- Participants Who Receives Vytorin In Usual Medical Practice Within Local Label For The First Time
Data sourced from ClinicalTrials.gov (NCT01070966). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.